Tags

Type your tag names separated by a space and hit enter

RETRACTED ARTICLE

A new plasma-adapted hydroxyethyl starch preparation: in vitro coagulation studies.
J Cardiothorac Vasc Anesth. 2010 Jun; 24(3):394-8.JC

Abstract

OBJECTIVE

Preparing hydroxyethyl starch (HES) in a plasma-adapted solution is supposed to improve safety with regard to coagulation. The influence of a new plasma-adapted HES preparation on coagulation was studied.

DESIGN

Operator-blinded, randomized study.

SETTING

Laboratory in vitro study.

PARTICIPANTS

Fifteen healthy young men scheduled for blood donation.

INTERVENTIONS

Blood was diluted by 10%, 30%, and 50% using either a plasma-adapted or nonplasma-adapted (prepared in saline solution) potato-derived 6% HES 130/0.42. Only the composition of the solvent of the 2 HES preparations was different.

MEASUREMENTS AND MAIN RESULTS

Rotation thromboelastometry (ROTEM; Pentapharm, Munich, Germany) was used to assess changes in coagulation; whole blood aggregometry with 3 inducers was used to assess effects of dilution with HES on platelet function. Clotting time (CT) and clot formation time were significantly prolonged by 30% and 50% dilution, showing significantly longer times in the non-plasma-adapted than in the plasma-adapted HES group (eg, intrinsic CT at the 30% dilution level: plasma-adapted HES 228 +/- 26 seconds [within normal range] v 269 +/- 29 seconds in the nonplasma-adapted HES group). Clot strengthening and clot firmness were significantly reduced by the non-plasma-adapted HES at the 30% dilution level. Platelet aggregation was significantly more reduced by the non-plasma-adapted HES at the 30% and 50% dilution levels.

CONCLUSIONS

Dilution with the nonplasma-adapted HES 130/0.42 was associated with more negative effects on thromboelastometry and platelet aggregation than the same HES 130/0.4 dissolved in a plasma-adapted solution. The benefits of using a plasma-adapted modern HES preparation on blood loss and use of blood/blood products in cardiac surgery need to be studied.

Authors+Show Affiliations

Department of Anesthesiology and Intensive Care Medicine, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany. BoldtJ@gmx.netNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Retracted Publication

Language

eng

PubMed ID

20005132

Citation

Boldt, Joachim, and Andinet Mengistu. "A New Plasma-adapted Hydroxyethyl Starch Preparation: in Vitro Coagulation Studies." Journal of Cardiothoracic and Vascular Anesthesia, vol. 24, no. 3, 2010, pp. 394-8.
Boldt J, Mengistu A. A new plasma-adapted hydroxyethyl starch preparation: in vitro coagulation studies. J Cardiothorac Vasc Anesth. 2010;24(3):394-8.
Boldt, J., & Mengistu, A. (2010). A new plasma-adapted hydroxyethyl starch preparation: in vitro coagulation studies. Journal of Cardiothoracic and Vascular Anesthesia, 24(3), 394-8. https://doi.org/10.1053/j.jvca.2009.09.014
Boldt J, Mengistu A. A New Plasma-adapted Hydroxyethyl Starch Preparation: in Vitro Coagulation Studies. J Cardiothorac Vasc Anesth. 2010;24(3):394-8. PubMed PMID: 20005132.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A new plasma-adapted hydroxyethyl starch preparation: in vitro coagulation studies. AU - Boldt,Joachim, AU - Mengistu,Andinet, Y1 - 2009/12/11/ PY - 2009/08/09/received PY - 2009/12/17/entrez PY - 2009/12/17/pubmed PY - 2010/8/24/medline SP - 394 EP - 8 JF - Journal of cardiothoracic and vascular anesthesia JO - J Cardiothorac Vasc Anesth VL - 24 IS - 3 N2 - OBJECTIVE: Preparing hydroxyethyl starch (HES) in a plasma-adapted solution is supposed to improve safety with regard to coagulation. The influence of a new plasma-adapted HES preparation on coagulation was studied. DESIGN: Operator-blinded, randomized study. SETTING: Laboratory in vitro study. PARTICIPANTS: Fifteen healthy young men scheduled for blood donation. INTERVENTIONS: Blood was diluted by 10%, 30%, and 50% using either a plasma-adapted or nonplasma-adapted (prepared in saline solution) potato-derived 6% HES 130/0.42. Only the composition of the solvent of the 2 HES preparations was different. MEASUREMENTS AND MAIN RESULTS: Rotation thromboelastometry (ROTEM; Pentapharm, Munich, Germany) was used to assess changes in coagulation; whole blood aggregometry with 3 inducers was used to assess effects of dilution with HES on platelet function. Clotting time (CT) and clot formation time were significantly prolonged by 30% and 50% dilution, showing significantly longer times in the non-plasma-adapted than in the plasma-adapted HES group (eg, intrinsic CT at the 30% dilution level: plasma-adapted HES 228 +/- 26 seconds [within normal range] v 269 +/- 29 seconds in the nonplasma-adapted HES group). Clot strengthening and clot firmness were significantly reduced by the non-plasma-adapted HES at the 30% dilution level. Platelet aggregation was significantly more reduced by the non-plasma-adapted HES at the 30% and 50% dilution levels. CONCLUSIONS: Dilution with the nonplasma-adapted HES 130/0.42 was associated with more negative effects on thromboelastometry and platelet aggregation than the same HES 130/0.4 dissolved in a plasma-adapted solution. The benefits of using a plasma-adapted modern HES preparation on blood loss and use of blood/blood products in cardiac surgery need to be studied. SN - 1532-8422 UR - https://www.unboundmedicine.com/medline/citation/20005132/A_new_plasma_adapted_hydroxyethyl_starch_preparation:_in_vitro_coagulation_studies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1053-0770(09)00352-8 DB - PRIME DP - Unbound Medicine ER -